Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 1 of 15 · 675 articles
Subtopics
People with Crohn's disease who develop symptomatic intestinal strictures currently often need endoscopic dilation or surgery. This trial tests an investigational oral drug (ontunisertib) aiming to improve...
A pediatric Phase 2 trial testing etrasimod could expand treatment options for children with moderately to severely active ulcerative colitis if later shown safe and effective. Families of affected children and their...
Perianal fistulas are a serious, common complication of Crohn's disease that are often difficult to heal. This study tests a real-world combination of surgery plus an approved IL-23 inhibitor (mirikizumab) to see if...
Early-phase mechanistic trials test how a new drug affects disease biology and safety; results can help decide whether larger trials should follow.
If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...
Cure8 found this source from Journal of paediatrics and child health, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Upadacitinib. Open the original...
This paper explores whether individualized integrative management including traditional Chinese medicine might influence outcomes in patients with biologic‑refractory, surgery‑intended acute severe ulcerative colitis — a...
The study links TXNIP/NLRP3 inflammatory signaling to disease features in an animal UC model and tests engeletin and rosuvastatin as interventions that lowered inflammatory markers—information relevant to researchers...
Colon-targeted delivery systems aim to concentrate drugs in the colon, which could improve effectiveness and reduce systemic side effects for IBD and colorectal cancer treatments. Understanding these approaches helps...
People with UC often look for dietary supplements or ‘‘natural’’ add-ons. This review explains which nutraceutical approaches have the most and least clinical support, helping patients and clinicians weigh potential...
Pharmacokinetics affect how well biologic drugs work for IBD. Better PK data could help explain why many patients have inadequate responses and could inform personalized dosing for IL-23p19 inhibitors used in Crohn’s...
Adding a mesalazine retention enema to oral mesalazine improved short-term symptom relief and endoscopic signs of mucosal healing in mild-to-moderate left-sided ulcerative colitis in this retrospective study. That could...
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
Comparative real-world data may help patients and clinicians weigh expected benefits and risks of risankizumab versus ustekinumab in Crohn’s disease, including effects on steroid-free remission and fistula healing.
This study suggests that using 5‑ASA drugs early in children with Crohn’s disease was common but linked to more steroid use, delayed biologic treatment, and lower biologic durability — outcomes that matter for long‑term...
NUDT15 variants strongly affect how people metabolize thiopurine drugs used in IBD; knowing variant frequency helps decide whether routine pre-treatment genotyping is useful in Iran and among specific ethnic groups.
CVID-related enteropathy can resemble celiac disease or IBD, carries high morbidity and mortality, and often does not respond to standard immunoglobulin therapy — patients and clinicians need awareness of its distinct...
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Infliximab, and Upadacitinib. The original article is from Medicina clinica.
Changes in SKYRIZI’s dosing or approval for a subcutaneous induction option in Crohn’s disease could affect how the drug is delivered and accessed. AbbVie’s acquisition strategy may broaden future treatment options but...
People receiving immune checkpoint inhibitors who develop colitis may face different risks of needing stronger immunosuppression depending on the ICI drug class. Understanding which features predict escalation could...
This study suggests commonly used GLP-1 receptor agonists (semaglutide, liraglutide) were associated with higher symptomatic and endoscopic remission in ulcerative colitis compared with matched controls. If validated,...
The article reviews current and emerging IBD treatments and the biological reasons they may work — useful for patients wanting to understand treatment options and future directions. It highlights therapies beyond...
Researchers are exploring new small molecules that might modulate T cells in IBD. This study found lab evidence of T‑cell inhibition for several compounds but no therapeutic benefit in a mouse colitis model, so these...
The FDA label confirms triamcinolone acetonide injectable suspension is indicated for short-term use to manage flares in regional enteritis (Crohn’s disease) and ulcerative colitis and summarizes important safety and...
People with ulcerative colitis considering or taking ozanimod or etrasimod may want to know about potential adverse events reported after these drugs entered the market, especially for nervous‑system, eye, and cardiac...
Insurance changes and rising premiums can force people with Crohn’s disease to skip or lose access to expensive biologic medications and routine care, which patients in the article say led to loss of treatment options...
The report describes a novel small-molecule inhibitor (IMYX-3) targeting RAB27A to reduce neutrophil-mediated damage in ulcerative colitis models, which could point to a new therapeutic approach if later validated in...
Cure8 could only read part of this source from AJN, American Journal of Nursing, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Golimumab, and Biosimilars.
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
This real-world multicentre study evaluates risankizumab effectiveness and short-term persistence in adults with Crohn's disease, including those previously treated with ustekinumab — information that can help patients...
Cure8 indexed source-provided abstract text from CABI Publishing, but this record did not meet the threshold for a full Cure8 brief. It is tagged for Inflammatory bowel disease and Medications.
Researchers are testing whether targeting fungi with fluconazole can boost how well IL-23 biologics work for Crohn’s disease — if positive, this could point to a new adjunctive strategy to improve responses to biologic...
The trial could show whether a smart-label app plus clinician alerts improves medication adherence and downstream clinical outcomes for people with Crohn's disease or ulcerative colitis starting oral or subcutaneous...
An expanded access program can allow people with Crohn's disease or ulcerative colitis to access upadacitinib before local approval when no other suitable treatments exist.
People with IBD on biologics or small molecules who live in or travel to areas where Coccidioides is endemic face a measurable risk of coccidioidomycosis. How the infection is classified (proven/probable/possible)...
The study tests a new mechanism (TL1A inhibition) that may reduce inflammation and fibrosis in IBD. Positive phase 2b results suggest duvakitug could become another treatment option if later trials confirm benefit and...
The work identifies an endogenous peptide (Tβ4) that is reduced in IBD and shows that replacing it in mice lessens colitis and intestinal fibrosis, pointing to a new potential treatment target for inflammation and...
This article summarizes positive phase IIb trial results for duvakitug (anti‑TL1A) in moderate‑to‑severe Crohn’s disease and ulcerative colitis, which could lead to a new targeted treatment option if later phase trials...
Depression is common in people with IBD and can worsen quality of life and disease outcomes. This trial explores whether mirtazapine—an antidepressant thought to have favorable gastrointestinal tolerability—can be...
This analysis suggests upadacitinib works and has a similar safety and pharmacokinetic profile in East Asian patients with moderately to severely active ulcerative colitis as in the global trials, which may reassure...
Because it describes a severe new Crohn’s disease case temporally linked to COVID‑19, patients and clinicians should be aware that persistent or worsening GI symptoms after SARS‑CoV‑2 infection may merit investigation;...
Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...
Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Complications. The original article is from JAAD case reports.
Patients with ulcerative colitis and PSC face higher risk of pouch inflammation after IPAA. The study reports fewer pouchitis events among the small group who received antibiotics or immunosuppression, which could...
Extraintestinal symptoms such as fatigue and joint pain significantly affect quality of life in Crohn's disease. This review suggests ustekinumab may help reduce fatigue and arthritis/arthralgia more than TNF antagonists...
The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...
Hepatitis E can cause elevated liver enzymes in people with IBD on biologics or small molecules. This series found infections were acute and resolved without chronic infection, and advanced therapy could be restarted....
This study highlights changing patterns of IBD presentation and treatment over 26 years in a large Hispanic cohort, which may affect outcomes and access-to-care discussions for Hispanic patients.
